**Supplementary Table 5. Clinical characteristics of cross-sectional cohorts A and B**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| variable | Cohort A (n=993)  |  | Cohort B (n=357) |  |
|  | HBeAg positive | HBeAg negative | *P*-value | HBeAg positive | HBeAg negative | *P*-value |
| Number | 649 | 344 |  | 231 | 126 |  |
| Sex (male/female) | 398/251 | 199/145 |  | 152/79 | 92/34 |  |
| Age (years) | 25 (15, 33) | 39 (30, 46) | <0.01 | 36 (30, 44) | 43 (34, 52) | <0.01 |
| ALT (U/L) | 71 (38, 143) | 29 (18, 55) | <0.01 | 48 (31, 91) | 40 (27, 57) | <0.01 |
| AST (U/L) | 53 (32, 100) | 27 (20, 41) | <0.01 | 36 (27, 55) | 32 (25, 40) | <0.01 |
| GGT(U/L) | 24 (15, 45) | 14 (20, 33) | <0.01 | 28 (17, 41) | 23 (12, 38) | <0.01 |
| HBeAg status (positive/negative) | 649/0 | 0/344 |  | 231/0 | 0/126 |  |
| anti-HBe(positive/negative) | 120/529 | 289/55 |  | 21/210 | 123/3 |  |
| Log (HBV DNA) | 7.82 (6.91, 8.48) | 3.55 (2.63, 4.87) | <0.01 | 7.08 (5.73, 7.89) | 4.28 (3.12, 5.30) | <0.01 |
| Fibrosis stage (0-1 vs 2-4) | 304/345(46.8%/ 53.2%) | 137/207(39.8%/ 60.2%) | 0.03 | 135/96(58.4%/41.6%) | 71/55(56.3%/ 43.7%) | 0.70 |
| Liver necroinflammatory grade (0-1vs 2-4) | 279/370(43.0%/ 57.0%) | 235/109(68.3%/31.7%) | <0.01 | 158/73(68.4%/31.6%) | 91/35(72.2%/27.8%) | 0.45 |

HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase.